The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors.
 
Wasiru Olugbenga Saka
No Relationships to Disclose
 
Simon Pacey
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Institute of Cancer Research
Travel, Accommodations, Expenses - Astellas Pharma
 
Fiona Helen Blackhall
No Relationships to Disclose
 
Javier Garcia-Corbacho
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Alberto Fusi
No Relationships to Disclose
 
Ioannis Karydis
No Relationships to Disclose
 
Mirela Hategan
No Relationships to Disclose
 
Glenda Laviste
No Relationships to Disclose
 
Sarah E. R. Halford
No Relationships to Disclose
 
Caroline Foxton
Patents, Royalties, Other Intellectual Property - Cancer Reseaarch Technology
Travel, Accommodations, Expenses - AstraZeneca
 
Robert McLeod
No Relationships to Disclose
 
Susan Wan
No Relationships to Disclose
 
Denis Charles Talbot
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Lilly (Inst); Pfizer (Inst)